A real-world study on the heterogeneity of HER2 status in the primary lesions and recurrent/metastatic lesions of patients with advanced breast cancer with primary HER2-low expression: a retrospective cohort study
Article|更新时间:2026-06-22
|
A real-world study on the heterogeneity of HER2 status in the primary lesions and recurrent/metastatic lesions of patients with advanced breast cancer with primary HER2-low expression: a retrospective cohort study
Chin OncolVol. 36, Issue 5, Pages: 470-478(2026)
作者机构:
南京医科大学附属肿瘤医院肿瘤内科,江苏 南京 210009
作者简介:
YUAN Yuan E-mail:yyuanyuan810122@126.com
基金信息:
Scientific Research Project of the Health Commission of Jiangsu Province(K2024068)
LI S Y, XU T, HUANG J Y, et al. A real-world study on the heterogeneity of HER2 status in the primary lesions and recurrent/metastatic lesions of patients with advanced breast cancer with primary HER2-low expression: a retrospective cohort study[J]. Chin J Oncol, 2026, 36(5): 470-478.
LI S Y, XU T, HUANG J Y, et al. A real-world study on the heterogeneity of HER2 status in the primary lesions and recurrent/metastatic lesions of patients with advanced breast cancer with primary HER2-low expression: a retrospective cohort study[J]. Chin J Oncol, 2026, 36(5): 470-478.DOI: 10.19401/j.cnki.1007-3639.2026.05.005.
A real-world study on the heterogeneity of HER2 status in the primary lesions and recurrent/metastatic lesions of patients with advanced breast cancer with primary HER2-low expression: a retrospective cohort study
Application progress of single-cell sequencing technology in breast cancer research
Effect of miR-107 targeting NKD1 on mitochondrial oxidative phosphorylation in breast cancer cells
Chinese expert consensus on standardized management of PI3K/AKT inhibitor-associated hyperglycemia in breast cancer (2026 edition)
2025 research hotspots and prospects of endocrine therapy for HR+/HER2- breast cancer
Progress and outlook of fundamental and translational breast cancer research in China, 2025
Related Author
Qiang LIU
Yi FANG
Jing WANG
LIU Dan
SHI Bin
XIAO Wen
WANG Jia
MA Xiaolan
Related Institution
Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Department of Medical oncology Ⅱ, General Hospital of Ningxia Medical University
Department of Emergency, General Hospital of Ningxia Medical University
Department of Pathology, Yinchuan Maternal and Child Health Care Hospital
Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region